Citations

Mayo Clinic

Showing 10 of 108599 citations.

P628: UPDATED ANALYSIS OF BELLWAVE-001: A PHASE 1/2 OPEN-LABEL DOSE-EXPANSION STUDY OF THE EFFICACY AND SAFETY OF NEMTABRUTINIB FOR THE TREATMENT OF B-CELL MALIGNANCIES
Woyach, Jennifer A. , Eradat, Herbert, Brander, Danielle M. , Tees, Michael, Ghori, Razi , Farooqui, Mohammed, Flinn, Ian W. , Awan, Farrukh T. , Parikh, Sameer A. , Phillips, Tycel , Paydar, Ima , Byrd, John C. , Stephens, Deborah M.

HemaSphere | August 21, 2023 | Volume: 7 | Issue: S3 | Pages: e7809236

10.1097/01.hs9.0000969416.78092.36 Get It

Nonatheromatous Coronary Kink Causing Angiographic Obstruction: A Rare Structural Anomaly
Jhawar, Nikita , Gharacholou, S. Michael , Michael Gharacholou, S , Jhawar, N , Prasad, Abhiram

Case Reports in Cardiology | August 21, 2023 | Volume: 2023 | Issue: No issue available | Pages: 1-5

10.1155/2023/6626263 | PMID 37645685 Get It

Ischemic symptoms may be explained by a multitude of coronary pathologies, including coronary artery tortuosity, atherosclerosis, fibromuscular dysplasia, vasculitis, coronary vasospasm, or microvascular disease. We present an unusual case of coronary kinking in a patient presenting with exertional jaw pain in the absence of atherosclerotic risk factors. Multimodality imaging, coronary imaging, and coronary physiology helped establish the diagnosis and guide management.
S223: REAL-WORLD EARLY OUTCOMES OF AXICABTAGENE CILOLEUCEL FOR RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Jacobson, Caron A. , Hemmer, Michael, Hu, Zhen‐Huan , Popplewell, Leslie , Best, Timothy, Beygi, Sara , Miao, Harry , Fu, Christine, Xu, Hairong , Pasquini, Marcelo C. , Frank, Matthew J. , Ahmed, Nausheen , Lin, Yi , Sun, Fang

HemaSphere | August 21, 2023 | Volume: 7 | Issue: S3 | Pages: e31464ce

10.1097/01.hs9.0000967804.31464.ce Get It

Predictors of intracranial hemorrhage in patients with atrial fibrillation treated with oral anticoagulants: Insights from the GARFIELD‐AF and ORBIT‐AF registries
Lim, Toon Wei , Camm, Alan John , Virdone, Saverio , Singer, Daniel E. , Bassand, Jean Pierre, Fonarow, Gregg C. , Ezekowitz, Michael D. , Kayani, Gloria , Kakkar, Ajay K. , Mahaffey, Kenneth W. , Pieper, Karen S. , Piccini, Jonathan P. , Investigators, for the GARFIELD‐AF and ORBIT‐AF, Piccini, Jonathan P , Fox, Keith A.A. , Gersh, Bernard J. , Hylek, Elaine M. , Peterson, Eric D. , Investigators, for the GARFIELD‐AF and ORBIT‐AF

Clinical Cardiology | August 21, 2023 | Volume: 46 | Issue: 11 | Pages: 1398-1407

10.1002/clc.24109 | PMID 37596725 Get It

AbstractBackgroundAn unmet need exists to reliably predict the risk of intracranial hemorrhage (ICH) in patients with atrial fibrillation (AF) treated with oral anticoagulants (OACs).HypothesisAn externally validated model improves ICH risk stratification.MethodsIndependent factors associated with ICH were identified by Cox proportional hazard modeling, using pooled data from the GARFIELD‐AF (Global Anticoagulant Registry in the FIELD‐Atrial Fibrillation) and ORBIT‐AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) registries. A predictive model was developed and validated by bootstrap sampling and by independent data from the Danish National Patient Register.ResultsIn the combined training data set, 284 of 53 878 anticoagulated patients had ICH over a 2‐year period (0.31 per 100 person‐years; 95% confidence interval [CI]: 0.28–0.35). Independent predictors of ICH included: older age, prior stroke or transient ischemic attack, concomitant antiplatelet (AP) use, and moderate‐to‐severe chronic kidney disease (CKD). Vitamin K antagonists (VKAs) were associated with a significantly higher risk of ICH compared with non‐VKA oral anticoagulants (NOACs) (adjusted hazard ratio: 1.61; 95% CI: 1.25–2.08; p = .0002). The ability of the model to discriminate individuals in the training set with and without ICH was fair (optimism‐corrected C‐statistic: 0.68; 95% CI: 0.65–0.71) and outperformed three previously published methods. Calibration between predicted and observed ICH probabilities was good in both training and validation data sets.ConclusionsAge, prior ischemic events, concomitant AP therapy, and CKD were important risk factors for ICH in anticoagulated AF patients. Moreover, ICH was more frequent in patients receiving VKA compared to NOAC. The new validated model is a step toward mitigating this potentially lethal complication.
Bicuspid Aortic Valve and Thoracic Aortic Disease: Further Evidence of Clinically Silent but Deadly Risk to Family Members of Affected Individuals
Prakash, Siddharth K. , Michelena, Héctor I. , Milewicz, Dianna M. , Michelena, Hector I , Prakash, Siddharth K , Milewicz, Dianna M

Circulation | August 21, 2023 | Volume: 148 | Issue: 8 | Pages: 648-650

10.1161/circulationaha.123.065406 | PMID 37603605 Get It

Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma
Steiner, Raphaël , Hwang, Steven R. , Khurana, Arushi , Annunzio, Kaitlin , Allen, Pamela B. , Baird, Katelin , Paulino, Darina, Alderuccio, Juan Pablo , Lossos, Izidore S. , David, Kevin A. , Evens, Andrew M. , Pandya, Karan, Bair, Steven M. , Kamdar, Manali , Aqeel, Sheeba Ba, Torka, Pallawi , Lynch, Ryan C. , Smith, Stephen D. , Noorani, Mansoor, Nair, Ranjit, Fang, Penny , Dabaja, Bouthaina S. , Lee, Hun Ju , Epperla, Narendranath , Allen, Pamela Blair , Baird, Katelin , Alderuccio, Juan Pablo , Lossos, Izidore S , David, Kevin , Evens, Andrew M , Kamdar, Manali , Torka, Pallawi , Smith, Stephen D , Ahmed, Sairah , Vega, Francisco , Lee, Hun Ju , Hwang, Steven R , Habermann, Thomas M. , Epperla, Narendranath , Feng, Lei , Ahmed, Sairah , Vega, Francisco , Wu, Susan Y. , Pinnix, Chelsea C. , Gunther, Jillian Rebecca

Blood Advances | August 21, 2023 | Volume: 7 | Issue: 24 | Pages: 7485-7493

10.1182/bloodadvances.2023010700 | PMID 37603594 Get It

Abstract In the pivotal study ECHELON-1, brentuximab vedotin (BV), doxorubicin, vinblastine, and dacarbazine (A + AVD) demonstrated superior efficacy compared with bleomycin + AVD for the treatment of advanced-stage classic Hodgkin lymphoma (cHL). However, there are minimal available data regarding the frequency of dose reductions or omission of BV during curative therapy and the potential impact on patient outcomes. In a real-world analysis, we retrospectively reviewed the characteristics and outcomes of 179 patients with stage III or IV cHL treated with frontline A + AVD from January 2010 to April 2022. Treatment consisted of up to 1.2 mg/kg of BV and standard dose AVD IV on days 1 and 15 of each 28-day cycle for up to 6 cycles. At the time of treatment, the median patient age was 37 years, and a high-risk International Prognostic Score was observed in 46% of patients. Overall, 91% of patients received 6 cycles of AVD; 55% of patients did not receive the intended cumulative dose of BV (CDB); 28% of patients received two-thirds or less than the planned CDB. At a median follow-up time of 27.4 months (95% confidence interval [CI], 24.8-29), the median progression-free survival (PFS) was not reached, and the 12-month PFS was 90.3% (95% CI, 85.9-95.0). The impact of CDB on PFS was not significant (P = .15), nor was high CDB significantly associated with increased adverse events. In real-world experience, A + AVD is a highly effective treatment for patients with advanced-stage cHL, including for patients with prominent dose reductions of BV.
MULTIMODAL RETINAL IMAGING FINDINGS IN HARDIKAR SYNDROME
Adams, Olufemi E. , Adeleye, Olufunmilola , Hussein, Musse, Naravane, Ameay V. , Looysen, Tyler , Simmons, Michael A. , Tang, Peter H. , Adeleye, Olufunmilola , Simmons, Michael A., Montezuma, Sandra Rocio

RETINAL Cases & Brief Reports | August 21, 2023 | Volume: 18 | Issue: 6 | Pages: 707-711

10.1097/icb.0000000000001476 | PMID 37603453 Get It

Purpose: To describe the syndromic, clinical, and retinal findings of a patient with an extremely-rare genetic condition known as Hardikar syndrome (HS) with presentation of optical coherence tomography, fundus autofluorescence, fluorescein angiographic, and indocyanine green angiographic findings. Methods: Clinical course was detailed and followed over time with examinations and multimodal imaging. Patient and Results: A 17-year-old patient with HS was referred for possible retinitis pigmentosa. Dilated fundoscopic examination revealed large, multifocal cauliform patches of chorioretinal retinal pigment epithelium changes with retinal pigment epithelium drop-out involving the macula and periphery in both eyes. Additionally, an inactive choroidal neovascular membrane was present in the left eye. Multimodal imaging with optical coherence tomography, fundus autofluorescence, fluorescein angiography, and indocyanine green angiography correlated with the clinical findings of focal patches of chorioretinal degeneration in both eyes. Additionally, an anomalous finding of the superior retinal arterial vessels filling in tandem with the choroidal was present in the left eye. The patient's clinical findings were consistent with HS, and genetic testing with whole-exome sequencing revealed a pathogenic mutation in the MED12 gene, confirming diagnosis. Discussion and Conclusions: Hardikar syndrome is associated with retinal pigment epithelium degeneration, creating focal patches of pigmentary chorioretinal atrophic lesions. Vision loss can occur because of the development of choroidal neovascular membranes. The authors recommend close evaluation and follow-up for HS patients with multimodal retinal imaging.
Whole Blood Metal Levels in the Setting of an Oncologic Endoprosthesis: Is There Cause for Concern?
Houdek, Matthew T. , Couch, Cory G., Rose, Peter S. , Lewallen, David G. , Berry, Daniel J. , Kremers, Hilal Maradit , Houdek, Matthew T , Berry, Daniel J , Wyles, Cody C. , Taunton, Michael J.

Clinical Orthopaedics & Related Research | August 21, 2023 | Volume: 482 | Issue: 2 | Pages: 352-358

10.1097/corr.0000000000002805 | PMID 37603308 Get It

Abstract Background Massive modular endoprostheses have become a primary means of reconstruction after oncologic resection of a lower extremity tumor. These implants are commonly made with cobalt-chromium alloys that can undergo wear and corrosion, releasing cobalt and chromium ions into the surrounding tissue and blood. However, there are few studies about the blood metal levels in these patients. Question/purpose What is the whole blood cobalt and chromium ion level in patients with massive modular endoprostheses? Methods We performed a cross-sectional study of our total joints registry to identify patients with a history of an endoprosthetic reconstruction performed at our institution. Patients who were alive at the time of our review in addition to those undergoing an endoprosthetic reconstruction after an oncologic resection were included. Whole blood samples were obtained from 27 (14 male and 13 female) patients with a history of a lower extremity oncologic endoprosthesis. The median time from surgery to blood collection was 8 years (range 6 months to 32 years). Blood samples were collected and stored in metal-free ethylenediaminetetraacetic acid tubes. Samples were analyzed on an inductively coupled plasma mass spectrometer in an International Organization for Standardization seven-class clean room using polytetrafluoroethylene-coated instruments to reduce the risk of metal contamination. The analytical measuring range was 1 to 200 ng/mL for chromium and cobalt. Cobalt and chromium levels were considered elevated when the blood level was ≥ 1 ppb. Results Cobalt levels were elevated in 59% (16 of 27) of patients, and chromium levels were elevated in 26% (seven of 27). In patients with elevated metal ion values, 15 of 17 patients had a reconstruction using a Stryker/Howmedica Global Modular Replacement System implant. Conclusion Blood metal levels were elevated in patients who received reconstructions using modular oncology endoprostheses Future work is needed to establish appropriate follow-up routines and determine whether and when systemic complications occur because of elevated metal levels and how to potentially address these elevated levels when complications occur. Prospective and retrospective collaboration between multiple centers and specialty societies will be necessary to address these unknown questions in this potentially vulnerable patient group. Level of Evidence Level IV, therapeutic study.